{"Clinical Trial ID": "NCT01421017", "Intervention": ["INTERVENTION 1:", "IMQ+RT", "This arm was closed from 6/4-2014.", "Weeks 1 to 2: RT administered at a metastatic 6 Gy skin site on days 1, 3, 5, 8 and 10 (M-W-F-M-W)", "Weeks 1 to 8: day 1 to 5 of each week: imiquimod 5% cream applied to all skin sites at night, from day 1 after RT, day 6 to 7 of each week: rest period.", "Week 9: Assessment of responses", "Patients may continue to receive additional cycles (same regimen, RT given at a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.", "Radiation", "Imiquimod", "INTERVENTION 2:", "- TBX/IMQ/RT", "Week -1 (day-7): cyclophosphamide 200mg/m2 IV as a single infusion", "Weeks 1 to 2: RT administered at a metastatic 6 Gy skin site on days 1, 3, 5, 8 and 10 (M-W-F-M-W)", "Weeks 1-8: day 1-5 of each week: imiquimod cream 5% applied all sites at night, from day 1 after RT, day 6-7 of each week: rest period.", "Week 9: Assessment of responses", "Patients may continue to receive additional cycles (same regimen, RT given at a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.", "Radiation", "Imiquimod", "- Cyclophosphamide"], "Eligibility": ["Incorporation criteria:", "Patients with biopsy-confirmed breast cancer.", "For patients without measurable metastases at a distance, an area of skin metastases designated to not receive local treatment may be substituted. Patients with multiple (>= 2) metastatic sites (skin involvement not required), with at least one RECIST-measurable site, will be eligible for the CTX/RT cohort.", "Age >= 18 years.", "The performance status of the Eastern Cooperative Oncology Group 0-2.", "Patients should accept the aspiration of the tumour for the purposes required by the protocol.", "The concomitant systemic treatment of cancer (hormones, biologics or chemotherapy) can be continued if remote metastases do not respond (i.e. there is no complete or partial response) to this treatment for >= 8 weeks, according to the investigator's assessment.", "Patients should have adequate organ and bone marrow function as defined below:", "Absolute number of neutrophils >= 1330/microlitre", "Hemoglobin >= 9.0 grams/decilire", "Blisters >= 75,000/microlitre", "Total Bilirubine = < 1.5 X upper institutional limit of normal", "AST (aspartate aminotransferase) = < 2.5 X upper institutional limit of normal", "ALT (alanine aminotransferase) = < 2.5 X upper institutional limit of normal", "Creatinine = < 2 X upper limit of normal if patient has chronic renal failure and creatinine has been stable for > 4 months)", "Informed consent.", "- Exclusion criteria:", "- Brain metastases except resecation or irradiation and stability >= 4 weeks.", "\u2022 Concomitant treatment with other research workers.", "Patients who have received local treatment (radiotherapy, high-power corticosteroids, intra-lesional treatment, laser treatment or surgery) other than biopsy in the target area within 4 weeks prior to the first administration of the study agent.", "Patients who received hyperthermia in the target area within 10 weeks prior to the first dose of the study agent.", "Patients with uncontrolled haemorrhagic disorder.", "Patients (with skin metastases only) who will be treated with anticoagulant with heparins or coumadine at the time of biopsy (they are eligible if the anticoagulant can be maintained before biopsy according to the researchers).", "Patients with known immunodeficiency or receiving immunosuppressive treatments.", "History of allergic reactions to imiquimod or its excipients.", "\u2022 Uncontrolled intercurrent medical disease or psychiatric illness or social situations that would limit compliance with the requirements of the study.", "Pregnancy or lactation.", "Women of childbearing potential do not use medically acceptable contraceptive methods."], "Results": ["Performance measures:", "Systemic response rate of tumours (Full response + Partial response)", "The systemic tumour response refers to the response at the time of the best overall response. Response criteria are specially adapted from the criteria for assessing response in solid tumours for immunotherapists (Wolchok, et al., 2009).", "Duration: 9 weeks from the start of RT treatment", "Results 1:", "Title of the arm/group: IMQ+RT", "Description of the arm/group: This arm was closed from 6/04/2014.", "Weeks 1 to 2: RT administered at a metastatic 6 Gy skin site on days 1, 3, 5, 8 and 10 (M-W-F-M-W)", "Weeks 1 to 8: day 1 to 5 of each week: imiquimod 5% cream applied to all skin sites at night, from day 1 after RT, day 6 to 7 of each week: rest period.", "Week 9: Assessment of responses", "Patients may continue to receive additional cycles (same regimen, RT given at a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.", "Radiation", "Imiquimod", "Total number of participants analysed: 12", "Type of measurement: Number", "Unit of measurement: proportion of tumours.25 (.06 to.57)", "Results 2:", "Title of arm/group: CTX/IMQ/RT", "Description of the arm/group: Week -1 (day-7): cyclophosphamide 200mg/m2 IV as a single infusion", "Weeks 1 to 2: RT administered at a metastatic 6 Gy skin site on days 1, 3, 5, 8 and 10 (M-W-F-M-W)", "Weeks 1-8: day 1-5 of each week: imiquimod cream 5% applied all sites at night, from day 1 after RT, day 6-7 of each week: rest period.", "Week 9: Assessment of responses", "Patients may continue to receive additional cycles (same regimen, RT given at a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.", "Radiation", "Imiquimod", "- Cyclophosphamide", "Total number of participants analysed: 12", "Type of measurement: Number", "Unit of measure: proportion of tumours.083 (.002 to.38)"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/12 (16.67%)", "- blurred vision *0/12 (0.00 %)", "Breast pain *1/12 (8.33%)", "Fever *1/12 (8.33%)", "Tumor pain *2/12 (16.67%)", "Headache *0/12 (0.00 %)", "Pain in the extremities *0/12 (0.00%)", "\u2022 Breast infection *1/12 (8.33%)", "Skin infection *1/12 (8.33%)", "Benign neoplasms *1/12 (8.33%)", "Dysarthria *0/12 (0.00 %)", "*0/12 (0.00%)", "Adverse Events 2:", "Total: 3/12 (25.0%)", "- blurred vision *0/12 (0.00 %)", "Breast pain *0/12 (0.00 %)", "Fever *0/12 (0.00 %)", "*0/12 (0.00 %)", "Headache *1/12 (8.33%)", "Extremity pain *1/12 (8.33%)", "Breast infection *0/12 (0.00 %)", "Skin infection *1/12 (8.33%)", "Benign neoplasms *0/12 (0.00 %)", "Dysarthria *1/12 (8.33%)", "1/12 (8.33%)"]}